Pyrotinib
Cutaneous T-cell Lymphoma
BeiGeneSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Cutaneous T-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bexarotene Case Comprehensive Cancer Center | Phase 4 | BBB |
Romidepsin Walter Hanel | Phase 2 | BB |
e7777 Eisai Co., Ltd. | Phase 3 | BB |
Tucidinostat Peking Union Medical College Hospital | Phase 2 | B |
Tislelizumab BeiGene | Phase 2 | B |
View all 20 →
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →